Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CleanSpark Inc (CLSK) vs Cassava Sciences Inc (FLNA) Price & Performance

CleanSpark IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

CleanSpark Inc vs Cassava Sciences Inc — how do they compare? CleanSpark Inc trades at $13.38 (market cap $3.45B), while Cassava Sciences Inc trades at $1.12 (market cap $52.66M). The key difference: CleanSpark Inc is far larger — about 65.5× Cassava Sciences Inc's market cap, and CleanSpark Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

CLSKFLNA
Market Cap
$3.45B$52.66M
Sector
TechnologyHealth
52-Week High
$23.20$4.64
52-Week Low
$8.18$1.09
Enterprise Value
$4.31B-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CleanSpark Inc

CleanSpark (CLSK) trades at $12.36, down 3.81% today, with a bearish technical signal and recent earnings misses. The company reported a net loss margin of -67.66% for 2026 but announced a transformative $6.6 billion 20-year AI data center lease, shifting focus from Bitcoin mining to high-performance computing. Analyst consensus remains unanimously bullish with a $21.43 price target, highlighting growth potential despite current profitability challenges.

The outlook balances high growth potential from the AI pivot against significant execution risks and persistent losses. Near-term volatility is expected as the market assesses the company's ability to monetize new contracts and achieve sustainable profitability. The stock presents a high-risk, high-reward opportunity dependent on successful business model transition.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CleanSpark Inc

CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.

Read more on CLSK

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA